Compare KEQU & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | LIXT |
|---|---|---|
| Founded | 1906 | 2005 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.9M | 107.6M |
| IPO Year | 1995 | N/A |
| Metric | KEQU | LIXT |
|---|---|---|
| Price | $36.57 | $7.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.7K | ★ 408.0K |
| Earning Date | 03-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.22 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.03 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $33.27 | $2.44 |
| 52 Week High | $60.89 | $8.25 |
| Indicator | KEQU | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 59.27 |
| Support Level | $35.15 | $2.90 |
| Resistance Level | $41.25 | $7.64 |
| Average True Range (ATR) | 1.38 | 0.82 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 64.28 | 69.02 |
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.